Use of Convalescent Plasma Therapy among Hospitalized Coronavirus Disease 2019 (COVID-19) Patients: A Single-Center Experience
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
COVID-19 Disease has strained our healthcare system. Convalescent plasma has been used to treat emerging infectious diseases -Influenza A/B, SARS-CoV, Ebola virus and now SARS-CoV 2.
OBJECTIVE
This study aims to determine the outcome and clinical course of COVID-19 patients who received convalescent plasma transfusion at Cardinal Santos Medical Center.
METHODS
This is a retrospective cohort analytical study of 75 patients who received convalescent plasma.
RESULTS
Median time from admission to CP transfusion was 3 days. Majority of patients received additional therapies including dexamethasone (100%); Remdesivir (95%); antibiotics (100%), tocilizumab (65%); hemoperfusion (88%) or combination of these. Among the survivors, the median LOS was 15 days while non-survivors have a median LOS of 6 days. One patient (1.33%) had mild transfusion reaction. Four patients (5.33%) developed DVT despite anti-coagulation. There was improvement in the inflammatory markers (LDH pvalue 0.04, CRP pvalue 0.00, Ferritin pvalue 0.0001). There was improvement in the pulmonary parameters -increase in mean PaO2, mean SaO2, and mean PFR; and decrease in mean FiO2 and mean RR post-treatment. Median LOS is 14 days for the CP group vs 11 days for the non-CP group. Mortality rate among the CP group is 25.33% while the non-CP group was 26.67%. LOS and mortality rate did not reach statistical significance.
CONCLUSIONS
There was no significant difference in mortality and length of hospital stay in patients given CP vs controls. CP might have a role in the improvement of inflammatory markers and pulmonary status.
Article activity feed
-
SciScore for 10.1101/2021.02.16.21251824: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Consent: There were several reasons why these patients did not received convalescent plasma: 1) attending physicians discretion; 2) no available plasma with the same blood type; 3) they were admitted during the time where CP program was not yet available in our institution; OR 4) they were referred for CPT but did not give consent for plasma transfusion.
IRB: Ethical Considerations: The study proposal was reviewed and approved by the CSMC Research Ethics Review Committee.Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not …
SciScore for 10.1101/2021.02.16.21251824: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Consent: There were several reasons why these patients did not received convalescent plasma: 1) attending physicians discretion; 2) no available plasma with the same blood type; 3) they were admitted during the time where CP program was not yet available in our institution; OR 4) they were referred for CPT but did not give consent for plasma transfusion.
IRB: Ethical Considerations: The study proposal was reviewed and approved by the CSMC Research Ethics Review Committee.Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:One limitation of this study, is that antibody titer in the donors’ plasma was not quantitatively determined because of the unavailability of the test. It was seen in a large multi-center study by Joyner et al. that there’s a significant survival advantage in COVID-19 patients who were given high antibody titer plasma (>18.45 S/co) compared to low titer (<4.62 s/co).20 It might have contributed to the non-significant difference in the mortality rate and hospital stay seen in our study.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-